Epitalon vs GHK-Cu
Bioregulator Peptide · Copper Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
Epitalon
A synthetic tetrapeptide that activates telomerase to lengthen telomeres and restores pineal melatonin production; evidence concentrated in Russian clinical research.
GHK-Cu
A copper-binding tripeptide that modulates over 4,000 genes; decades of topical cosmetic use, zero controlled injectable trials.
Epitalon
132 studies
4 human trials
Not FDA-Approved
GHK-Cu
186 studies
4 human trials
Not FDA-Approved
What it does
Epitalon
Lengthens telomeres, the protective caps at the ends of chromosomes that shorten as cells divide. A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a bovine pineal gland extract.
GHK-Cu
Delivers copper to skin and tissue cells, where it switches on the genes that build collagen and switches off the ones that drive aging. Naturally produced by the body; levels decline about 60 percent between the 20s and 60s.
How it works
Epitalon
Epitalon binds to promoter regions of genes that code for telomerase (the enzyme that maintains telomere DNA), pineal melatonin synthesis enzymes, and antioxidant defenses (SOD-1, NQO1, catalase). The downstream effect is increased telomerase activity, telomere elongation past the Hayflick limit (the normal cellular division ceiling), and restored melatonin secretion in aged subjects. The compound is a synthetic version of a fragment originally identified in bovine pineal gland extract studied since the 1970s by the St. Petersburg Institute of Bioregulation and Gerontology.
GHK-Cu
GHK-Cu binds copper(II) and delivers it to tissue sites where copper-dependent enzymes drive repair: lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense, cytochrome c oxidase for cellular energy. It also directly modulates gene expression, upregulating collagen production and stem cell recruitment while downregulating the matrix-degrading enzymes that drive aging. The breadth of gene regulation (over 4,000 genes in transcriptomic studies) is unmatched among peptides, but gene expression changes in laboratory studies are not the same as clinical outcomes in humans.
How often
Epitalon
In published research, epitalon has been administered as subcutaneous or intramuscular injection over courses ranging from 10-day cycles repeated annually (the protocol used in the 266-patient prospective cohort study with epithalamin) to single-injection acute studies. Frequency and duration vary by indication and follow Russian research protocols predominantly published outside FDA-regulated frameworks.
GHK-Cu
Topical application in cosmetic skincare formulations with decades of commercial use history. Injectable form expected to return to legal pharmacy preparation status following the February 2026 HHS announcement. Published human research is topical; no consensus injectable dosing protocol exists in peer-reviewed literature.
How strong
Epitalon
The most extensively human-studied anti-aging peptide in PSI's library by trial volume in cellular aging endpoints. A 266-person prospective cohort with epithalamin (the source extract) reported 1.6 to 1.8-fold reduction in 6-year mortality. Human telomere elongation documented in blood cells of elderly subjects (ages 60 to 80). A retinitis pigmentosa clinical trial reported positive visual function outcomes in the majority of enrolled patients.
GHK-Cu
The widest gap between mechanistic promise and clinical validation of any compound in PSI's library. Over 4,000 genes modulated in transcriptomic analysis (Pickart and Margolina 2018). Topical cosmetic studies show measurable skin improvements. Zero controlled human trials for injectable systemic use. The mechanism is real; the human systemic evidence is not yet there.
Main tradeoff
Epitalon
Research base concentrated in Russian literature, predominantly from a single institute. Most landmark mortality and longevity studies use epithalamin (the source extract) rather than synthetic epitalon, leaving the synthetic-tetrapeptide-specific evidence base smaller than the source-extract evidence base. No large Western clinical trials. Not FDA-approved in the United States.
GHK-Cu
Topical GHK-Cu shows measurable improvements in skin thickness, elasticity, and fine lines in cosmetic studies. The copper-binding mechanism and gene expression profile are well-characterized across multiple independent research groups. Whether injectable GHK-Cu produces systemic anti-aging effects in humans is not established. Long-term safety of regular injectable administration is not characterized. As a naturally occurring peptide that declines approximately 60% between the 20s and 60s, the theoretical safety profile is favorable, but theoretical safety is not established safety.
Best for
Epitalon
- Cellular aging research where telomerase activation and telomere length are primary endpoints
- Pineal gland and melatonin restoration research, particularly in age-related circadian decline
- Anti-aging research with awareness of the Russian-literature concentration of the evidence base
GHK-Cu
- Research interest in copper-peptide mechanisms and broad gene modulation
- Research comparing topical versus systemic delivery of naturally occurring repair peptides
- Research contexts where the gap between transcriptomic promise and clinical validation is the central question
How to choose
A good fit for Epitalon
- Research on telomerase activation and telomere length as cellular aging endpoints
- Research on pineal gland function and age-related melatonin decline
- Research contexts where the 266-patient mortality cohort data (using source extract) is relevant
A good fit for GHK-Cu
- Research on broad gene-expression modulation through copper-peptide delivery
- Research on topical skincare and wound healing mechanisms
- Research contexts where multiple independent research groups and international evidence matter
Consider both across time
Both are anti-aging-coded peptides but operate through fundamentally different molecular mechanisms. Epitalon targets telomerase activation (chromosomal aging) and pineal melatonin synthesis (circadian aging). GHK-Cu targets broad gene expression modulation through copper delivery (tissue-level aging). Neither has the clinical validation depth of FDA-approved anti-aging interventions. The comparison is most useful for researchers evaluating which anti-aging mechanism pathway to investigate further.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Gene Promoter Binding
- Gene Promoter Binding upregulates Telomerase Activity
- Telomerase Activity connects to Telomere Elongation
- Gene Promoter Binding upregulates Pineal Melatonin Synthesis
- Gene Promoter Binding upregulates Antioxidant Enzyme Expression (SOD-1, NQO1, catalase)
- Telomere Elongation connects to Cellular Longevity; Antioxidant Enzyme Expression (SOD-1, NQO1, catalase) connects to Cellular Longevity
- Copper(II) Delivery
- Copper(II) Delivery modulates TGF-beta Signaling
- Copper(II) Delivery activates Lysyl Oxidase Activation
- TGF-beta Signaling connects to Collagen Synthesis; Lysyl Oxidase Activation connects to Collagen Synthesis
- Copper(II) Delivery connects to MMP Suppression
- Collagen Synthesis connects to Tissue Remodeling; MMP Suppression connects to Tissue Remodeling
- Copper(II) Delivery connects to Broad Gene Modulation (4,000+)
Epitalon binds promoter regions of genes coding for telomerase and pineal melatonin synthesis enzymes, increasing telomerase activity and restoring melatonin production.
GHK-Cu binds copper(II) and delivers it to tissue sites, where it modulates over 4,000 genes including those that build collagen.
Research Evidence
Both compounds have human data but of different types and in different domains. Epitalon's evidence base includes a 266-patient prospective mortality cohort with epithalamin (the source extract), telomere elongation studies in elderly subjects, and a retinitis pigmentosa trial, predominantly from Russian research programs. GHK-Cu's evidence includes topical cosmetic studies showing measurable skin improvements, extensive transcriptomic profiling (4,000+ gene modulations), and broad preclinical tissue coverage. Neither has completed the specific trial packages Western regulatory agencies require for drug approval.
- 1.
For skin and visible aging, GHK-Cu has more directly relevant research and practical applications.
- 2.
For cellular longevity research, epitalon targets a more fundamental aging mechanism but with less independent validation.
- 3.
For a practical anti-aging protocol, GHK-Cu has more accessible and better-validated applications.
- 4.
For theoretical longevity interest, epitalon's telomerase mechanism is compelling but clinically unproven.
Key Limitations
- •No head-to-head comparison exists.
- •Both are Animal Studies, neither has robust clinical evidence for anti-aging claims.
- •Epitalon's evidence base lacks independent replication.
- •'Anti-aging' is a broad claim, neither compound has proven it extends human healthspan or lifespan.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Epitalon
"Epitalon reversed my biological age by 5 years"
Insufficient evidence
"Epitalon is the most proven anti-aging peptide"
Overstated
"I sleep much better after an epitalon cycle"
Plausible mechanism
GHK-Cu
"GHK-Cu is the best anti-aging peptide for skin"
Plausible but unproven
"It regrew my hair"
Anecdotal only
"Topical is just as effective as injections"
Anecdotal only
Safety Comparison
Both compounds have limited Western-standard safety data for injectable use. Epitalon's safety data comes primarily from Russian clinical trials with no serious adverse events reported across published studies. GHK-Cu has decades of topical cosmetic safety data but limited injectable safety characterization. As a naturally occurring peptide that declines with age, GHK-Cu has a favorable theoretical safety profile. Neither compound is FDA-approved.
Epitalon
Very limited safety data. Most studies come from a single Russian research group. No serious adverse events reported in available literature, but the data is thin.
GHK-Cu
Well-tolerated topically. Endogenous compound, your body already produces it, though levels decline with age. Limited safety data for injectable use at therapeutic doses.
What the Research Suggests
Both are interesting research compounds with different theoretical advantages. GHK-Cu has more diverse, independently replicated evidence. Epitalon has a more ambitious target (telomeres) but a weaker evidence foundation. Neither has proven anti-aging effects in rigorous human trials.